DrugBank ID: db00433
Synonymous :2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine | 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine | 3-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine | capazine | chlormeprazine | chloro-3 (n-methylpiperazinyl-3 propyl)-10 phenothiazine | chloropernazine | n-(gamma-(4’-methylpiperazinyl-1’)propyl)-3-chlorophenothiazine | prochlorperazin | prochlorpérazine | prochlorperazine | prochlorperazinum | prochlorpermazine | prochlorpromazine | procloperazine | proclorperazina
Drug Sentece Context
Table 1. Analysis of context sentence of prochlorperazine gene in 3 abstracts.
|32616067||To be included in the trial the participant MUST: 1) Have given written informed consent to participate 2) Be aged 18 years to 70 years 3) Not previously have been diagnosed with COVID-19 4) Work in a high-risk secondary or tertiary healthcare setting (hospitals accepting COVID-19 patients) with direct patient-facing care EXCLUSION CRITERIA: The presence of any of the following will mean participants are ineligible: 1) Known COVID-19 positive test at baseline (if available) 2) Symptomatic for possible COVID-19 at baseline 3) Known hypersensitivity reaction to hydroxychloroquine, chloroquine or 4-aminoquinolines 4) Known retinal disease 5) Known porphyria 6) Known chronic kidney disease (CKD; eGFR<30ml/min) 7) Known epilepsy 8) Known heart failure or conduction problems 9) Known significant liver disease (Gilbert’s syndrome is permitted) 10) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 11) Currently taking any of the following contraindicated medications: Digoxin, Chloroquine, Halofantrine, Amiodarone, Moxifloxacin, Cyclosporin, Mefloquine, Praziquantel, Ciprofloxacin, Clarithromycin, Prochlorperazine, Fluconazole 12) Currently taking hydroxychloroquine or having a clinical indication for taking hydroxychloroquine 13) Currently breastfeeding 14) Unable to be followed-up during the trial 15) Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies) before study follow-up visit 16) Not able to use or have access to a modern phone device/web-based technology 17) Any other clinical reason which may preclude entry in the opinion of the investigator INTERVENTION AND COMPARATOR: Interventions being evaluated are: A) Daily hydroxychloroquine or B) Weekly hydroxychloroquine or C) Placebo The maximum treatment period is approximately 13 weeks per participant.|
|32949606||The goal of this paper was to summarize the current literature on activity toward RNA-viruses of such drugs like chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine. […] Chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine possess anti-viral activity towards different types of viruses.|